Immunomic, Colmmune partner on cancer immunotherapy

By The Science Advisory Board staff writers

November 20, 2020 -- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs.

ITI will use CoImmune's process for manufacturing and current good manufacturing practice (cGMP) work for the advancement of ITI-1020, ITI's autologous dendritic cell (DC) investigational vaccine loading with messenger RNA encoding pp65-lysosome-associated membrane glycoprotein (LAMP). The vaccine will be used to treat newly diagnosed glioblastoma.

CoImmune is eligible to receive milestone payments from ITI upon the successful achievement of certain agreed-upon goals, such as initiation of clinical studies and regulatory submissions. CoImmune will also be eligible to receive royalty payments based upon net sales of ITI-1020, if the product is approved in the future, the firms said.

ITI, Replicate Bioscience partner on RNA technologies
Immunomic Therapeutics (ITI) and Replicate Bioscience have entered into a research and licensing option agreement to combine their technologies to combat...
Immunomic Therapeutics inks license deal with Ichor
Immunomic Therapeutics (ITI) has signed a licensing agreement with Ichor Medical Systems to support the development of its ITI-1001 investigational plasmid...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter